久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

  • Lantern Pharma and NCI expand oncology partnership pharmaceutical-business-review
    January 13, 2022
    Lantern Pharma and the US National Institutes of Health unit National Cancer Institute’s (NCI) Developmental Therapeutics Branch (DTB) have announced...
  • Lantern Pharma Reacquires Irofulven from Allarity Therapeutics contractpharma
    July 29, 2021
    ?Allarity Therapeutics A/S and Lantern Pharma Inc. have entered an exclusive agreement under which Lantern will reacquire global rights to Irofulven (LP-100) and assume full responsibility for future clinical development and commercialization.
PharmaSources Customer Service